Obesity Medicine

GLP-1 use was associated with lower overall cancer risk, with the strongest associations observed for endometrial and ovarian cancers and meningioma.

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses challenges to diagnosing and treating venous disease in patients with obesity.

A Cleveland Clinic trial revealed that AI-driven precision treatment significantly reduced HbA1c and body weight, often eliminating need for medications other than metformin.

A recent study showed obesity in childhood or adolescence accelerates biological aging by up to 48% in young adults.

The GLP-1/GIP receptor agonist also showed promise in an exploratory maintenance arm, producing rapid weight loss at an induction dose that was sustained after down-titration.

Your daily dose of the clinical news you may have missed.

RDX-002, an investigational, first-in-class therapeutic, significantly reduced weight regain after cessation of antiobesity treatment with semaglutide and tirzepatide.

Jonathan Bonnet, MD, MPH, board certified in lifestyle and obesity medicine, explains how the 6 pillars of the former are essential to success in the latter.

The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.

Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.